The rationale being that such an approach might identify selective inhibitors of the pro-tumourigenic actions of TGF-β which, in contrast to known TGF-β receptor kinase inhibitors, would not inhibit the tumour suppressor pathways of TGF-β. The gene discussed is TGFB1; the disease is neoplasm.